BİR KEZ EKSTAZİ KULLANIMINA BAĞLI GELİŞEN BİR OBSESİF KOMPULSİF BOZUKLUK OLGUSU

Ü. B. Semiz; A. Algül; C. Güneş; A. Ateş; C. Başoğlu; S. Ebrinç; M. Çetin

BİR KEZ EKSTAZİ KULLANIMINA BAĞLI GELİŞEN BİR OBSESİF KOMPULSİF BOZUKLUK OLGUSU

Yazarlar

Ü. B. Semiz
A. Algül
C. Güneş
A. Ateş
C. Başoğlu
S. Ebrinç
M. Çetin

Anahtar Kelimeler:

ekstazi kullanımı

Özet

Ekstazi (3, 4-methylenedioxymethamphetamine, MDMA), toplumda yaygın olarak kötüye kullanılan bir maddedir. Literatürde ekstaziye bağlı olarak ortaya çıktığı düşünülen ve ısrarlı şekilde süren birçok farklı psikiyatrik bozukluk bildirilmiştir. Ekstazinin serotonerjik nöronlarda kalıcı hasar oluşturduğuna ilişkin kanıtlar giderek artmaktadır. Bu makalede bir kez ekstazi kullanımı sonrası gelişen bir obsesif kompulsif bozukluk (OKB) olgusu sunulmuştur. Olgunun, ekstazi kullanımından sonra yorgunluk ve pişmanlık hissettiği, daha sonra ekstazi tozu bulaşmış olabileceği ve bunu yanlışlıkla yutabileceği korkusuyla ellerini hiçbir yere dokunduramadığı, sürekli ellerini yıkama ihtiyacı hissettiği, son bir senedir yakınmalarına dini içerikli takıntılarının eklendiği, daha önce herhangi bir psikiyatri doktoruna gitmediği ve tedavi kullanmadığı anlaşılmıştır. Bu yazıda olgudan hareketle, ekstazinin olası etki mekanizmaları ve nöronal düzeyde yaptığı etkiler gözden geçirilmiştir.

Kaynaklar

Ögel K, Çorapçıoğlu A, Tot Ş ve ark. Türkiye’de ortaöğretim gençliği arasında ecstasy kullanımı. Bağımlılık Dergisi 2003; 4:67-71.

McCann UD, Slate SO, Ricaurte GA. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; ‘ecstasy’). Drug Saf 1996; 15:107-115.

Ricaurte GA, Yuan J, McCann UD. 3,4-Methylenedioxy-methamphetamine (MDMA, ‘Ecstasy’)-induced serotonin-neurotoxicity: Studies in animals. Neuropsychobiology 2000; 42:5-10.

Thomasius R, PeterseKU, Zapletalova P ve ark. Mental disorders in current and former heavy ecstasy (MDMA) users. Addiction 2005; 100:1310.

Ricaurte GA, DeLanney LE, Irwin I ve ark. Toxic effects of MDMA on central serotonergic neurons in the primate: Importance of route and frequency of drug administration. Brain Res 1988; 446:165-168.

Insel TR, Battaglia G, Johannessen JN ve ark. 3,4-Methylenedioxy-methamphetamine (‘‘ecstasy’’) selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 1989; 249:713-720.

Battaglia G, Yeh SY, De Souza EB. MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons. Pharm Biochem Behav 1988; 29:269-274.

McCann UD, Eligulashvili V, Ricaurte GA. 3,4Methylenedioxymeth-amphetamine (‘‘ecstasy’’)-induced serotonin neurotoxicity: Clinical studies. Neuropsychobiology 2000; 42:11-16.

Pennings EJ, Konijn KZ, de Wolff FA. Clinical and toxicologic aspects of the use of ecstasy. Ned Tijdschr Geneeskd 1998;142:1942-1946.

McDowell DM, Kleber HD. MDMA: its history and pharmacology. Psychiatr Ann 1994; 24:127-130.

Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (‘‘ecstasy’’) in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998; 19: 241-251.

Vollenweider FX, Liechti ME, Gamma A ve ark. Acute psychological and neurophysiological effects of MDMA in humans. J. Psychoactive Drugs 2002; 34: 171-184.

Perani D, Colombo C, Bressi S ve ark. [18F]FDG PET study in obsessive–compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry 1995; 166:244–250.

Hansen ES, Hasselbalch S, Law I, Bolwig TG. The caudate nucleus in obsessive–compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study. Int J Neuropsychopharmacol 2002; 5:1–10.

Saxena S, Brody AL, Ho ML ve ark. Differential cerebral metabolic changes with paroxetine treatment of obsessive–compulsive disorder vs major depression. Arch Gen Psychiatry 2002;59:250–261.

Adams KH, Hansen ES, Pinborg LH ve ark. Patients with obsessive–compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol 2005; 8:391–401.

Schifano F. Potential human neurotoxicity of MDMA (‘Ecstasy’): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. Neuropsychobiology 2000; 42:25-33.

Parrott AC, Sisk E, Turner JJ. Psychobiological problems in heavy ‘ecstasy’ (MDMA) polydrug users. Drug Alcohol Depend 2000; 60:105-110.

Sanchez V, Camarero J, Esteban B ve ark. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA (‘ecstasy’)-induced degeneration of 5-HT nerve endings in rat brain. Br J Pharmacol 2001;134:46-57.

McCann UD, Eligulashvili V, Mertl M ve ark. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4methylenedioxymethamphetamine (MDMA) users. Psychopharmacology 1999; 147:56-65.

Ricaurte GA, Finnegan KT, Irwin I, Langston JW. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: Preliminary observations. Ann NY Acad Sci 1990; 600:699-710.

Goldberg HL, Finnerty RJ . The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 1979; 136:1184-1187.

Yocca FD. Novel Anxiolytic Agents: Actions on Specific Subtypes of Central 5-HT Receptors, Current and Future Trends in Anticonvulsant, Anxiety and Stroke Therapy, BS Meldrum, M Williams (Eds.), New York, Wiley-Liss, 1990, 145-167.

Rang HP, Dale MM, Ritter JM. Pharmacology, 4. baskı, Edinburgh, Churchill Livingstone, 1999; 528-538.

Olivier B, van Wijngaarden I, Soudijn W. 5-HT3 receptor antagonists and anxiety; a preclinical review. Eur Neuropsychopharmacol 2000; 10:77-95.

McCann UD, Ricaurte GA. Lasting neuropsychiatric sequelae of (+/-)3,4-methylenedioxymethamphetamine (‘ecstasy’) in recreational users. J Clin Psychopharmacol 1991; 11:302-305.

Parrott AC, Milani RM, Parmar R, Turner JD. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 2001;159:77-82.

Semiz UB, Başoğlu C, Çetin M, Erinç S. Panic disorder due to ingestion of single dose ecstasy: A case report. International Journal of Psychiatry in Clinical Practice 2005; 9: 0-00

Ricaurte GA, Martello AL, Katz JL, Martello MB. Lasting effects of (+/-)3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in non-human primates: neurochemical observations. J Pharmacol Exp Ther 1992; 261:616-622.

De Souza EB, Battaglia G, Insel TR. Neurotoxic effects of MDMA on brain serotonin neurons: Evidence from neurochemical and radioligand binding studies. Ann NY Acad Sci 1990;600:682-698.

Yocca FD. Novel Anxiolytic Agents: Actions on Specific Subtypes of Central 5-HT Receptors, Current and Future Trends in Anticonvulsant, Anxiety and Stroke Therapy, BS Meldrum, M Williams (Editors), New York: Wiley-Liss, 1990;145-67.

Oliver B, van Wijngaarden I, Soudijn W. 5-HT3 receptor antagonists and anxiety; a preclinical review. Eur Neuropsychopharmacol 2000; 10:77-95.

BİR KEZ EKSTAZİ KULLANIMINA BAĞLI GELİŞEN BİR OBSESİF KOMPULSİF BOZUKLUK OLGUSU